Beneficial ownership — 13D / 13G
87,387 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.
Coverage begins December 2024, when the SEC required these schedules to be filed as structured XML.
| Reporting person | Issuer | Schedule | % of class | Event date | Filed |
|---|---|---|---|---|---|
| Rubric Capital Management LP | SPRY ARS Pharmaceuticals, Inc. | 13G/A | 8.06% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | CRVS Corvus Pharmaceuticals, Inc. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| DISCIPLINED GROWTH INVESTORS INC /MN | GEOS Geospace Technologies Corp | 13G/A | 8.5% | Mar 31, 2026 | 6mo |
| RIVERNORTH CAPITAL MANAGEMENT, LLC | GLQ Clough Global Equity Fund | 13G/A | 6.55% | Mar 31, 2026 | 6mo |
| PERCEPTIVE ADVISORS LLC | AMLX Amylyx Pharmaceuticals, Inc. | 13G/A | 7.5% | Mar 31, 2026 | 6mo |
| Sirenia Capital Management LP | CCCC C4 Therapeutics, Inc. | 13G | 9.9% | Mar 31, 2026 | 6mo |
| METEORA CAPITAL, LLC | GTEN Gores Holdings X, Inc. | 13G/A | 7.26% | Mar 31, 2026 | 6mo |
| Sirenia Capital Management LP | OKYO OKYO Pharma Ltd | 13G | 7.7% | Mar 31, 2026 | 6mo |
| Nantahala Capital Management, LLC | ABEO Abeona Therapeutics Inc. | 13G/A | 9.99% | Mar 31, 2026 | 6mo |
| Manulife Investment Management (US) LLC | SBFG Sb Financial Group, Inc. | 13G/A | 7.47% | Mar 31, 2026 | 6mo |
| Anson Funds Management LP | SVIA Silvia, Inc. | 13G/A | 0.5% | Mar 31, 2026 | 6mo |
| VIKING GLOBAL INVESTORS LP | ORKA Oruka Therapeutics, Inc. | 13G/A | 5.3% | Mar 31, 2026 | 6mo |
| Shigeki Saitoh | KDK Kodiak AI, Inc. | 13G/A | 6.9% | Mar 31, 2026 | 6mo |
| North Reef Capital Management LP | MKTX Marketaxess Holdings Inc | 13G | 5.27% | Mar 31, 2026 | 6mo |
| Lineage Point Capital LP | BEBE TGE Value Creative Solutions Corp | 13G/A | 7.31% | Mar 31, 2026 | 6mo |
| Point72 Asset Management, L.P. | IOBTQ IO Biotech, Inc. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | EVGN Evogene Ltd. | 13G | 9.99% | Mar 31, 2026 | 6mo |
| RA CAPITAL MANAGEMENT, L.P. | DNTH Dianthus Therapeutics, Inc. | 13G/A | 4.8% | Mar 31, 2026 | 6mo |
| ORBIMED ADVISORS LLC | AVTX Avalo Therapeutics, Inc. | 13G/A | 2.1% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | RDNT RadNet, Inc. | 13G | 5.4% | Mar 31, 2026 | 6mo |
| Divisadero Street Capital Management, LP | OMDA Omada Health, Inc. | 13G | 9.9% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | UEC Uranium Energy Corp | 13G/A | 15.5% | Mar 31, 2026 | 6mo |
| First Trust Capital Management L.P. | RAAQ Real Asset Acquisition Corp. | 13G/A | 2.45% | Mar 31, 2026 | 6mo |
| Global X Management CO LLC | DNN Denison Mines Corp. | 13G/A | 7.07% | Mar 31, 2026 | 6mo |
| Orbis Investment Management Limited | FBIN Fortune Brands Innovations, Inc. | 13G/A | 0.6% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | AMRC Ameresco, Inc. | 13G/A | 10.2% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | UMH Umh Properties, Inc. | 13G/A | 4.3% | Mar 31, 2026 | 6mo |
| AMERIPRISE FINANCIAL INC | BUR Burford Capital Ltd | 13G/A | 5.6% | Mar 31, 2026 | 6mo |
| ADAR1 Capital Management, LLC | EQ Equillium, Inc. | 13G/A | 9.9% | Mar 31, 2026 | 6mo |
| T. Rowe Price Investment Management, Inc. | KYMR Kymera Therapeutics, Inc. | 13G | 6.7% | Mar 31, 2026 | 6mo |
| Timothy G. Youngquist 2020 Irrevocable Trust | CHRS Coherus Oncology, Inc. | 13G/A | 8.3% | Mar 31, 2026 | 6mo |
| Berkshire Hathaway Inc | LILA Liberty Latin America Ltd. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| GENDELL JEFFREY L | NINE Nine Energy Service, Inc. | 13G | 5.6% | Mar 31, 2026 | 6mo |
| Fund 1 Investments, LLC | GCO Genesco Inc | 13G/A | 3.92% | Mar 31, 2026 | 6mo |
| Manulife Investment Management (US) LLC | LARK Landmark Bancorp Inc | 13G/A | 4.94% | Mar 31, 2026 | 6mo |
| WELLINGTON MANAGEMENT GROUP LLP | ICLR Icon PLC | 13G/A | 7.7% | Mar 31, 2026 | 6mo |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | BURU Nuburu, Inc. | 13G | 9.9% | Mar 31, 2026 | 6mo |
| EdgePoint Investment Group Inc. | MAT Mattel Inc | 13G/A | 16.26% | Mar 31, 2026 | 6mo |
| Saba Capital Management, L.P. | OIM OneIM Acquisition Corp. | 13G/A | 6.43% | Mar 31, 2026 | 6mo |
| ARMISTICE CAPITAL, LLC | ARDS Aridis Pharmaceuticals Inc. Common Stock | 13G/A | 11.43% | Mar 31, 2026 | 6mo |
| Orbis Investment Management Limited | PRAX Praxis Precision Medicines, Inc. | 13G/A | 8.9% | Mar 31, 2026 | 6mo |
| PRICE T ROWE ASSOCIATES INC /MD/ | LSCC Lattice Semiconductor Corp | 13G/A | 11.8% | Mar 31, 2026 | 6mo |
| Pentwater Capital Management LP | GEO Geo Group Inc | 13G | 7.2% | Mar 31, 2026 | 6mo |
| Sirenia Capital Management LP | OVID Ovid Therapeutics Inc. | 13G | 9.9% | Mar 31, 2026 | 6mo |
| EMINENCE CAPITAL, LP | GTLB Gitlab Inc. | 13G/A | 0% | Mar 31, 2026 | 6mo |
| EAGLE CAPITAL MANAGEMENT LLC | AER AerCap Holdings N.V. | 13G/A | 4.38% | Mar 31, 2026 | 6mo |
| HARRIS ASSOCIATES L P | WEN Wendy's Co | 13G/A | 3.1% | Mar 31, 2026 | 6mo |
| SOUTHEASTERN ASSET MANAGEMENT INC/TN/ | GLIBA Liberty Capital Corp | 13G/A | 3.68% | Mar 31, 2026 | 6mo |
| Nantahala Capital Management, LLC | PTON Peloton Interactive, Inc. | 13G | 7.31% | Mar 31, 2026 | 6mo |
| Bay Pond Partners, L.P. | CUBI Customers Bancorp, Inc. | 13G/A | 5% | Mar 31, 2026 | 6mo |